Abstracts tagged "Questionnaires and spondylarthropathy"

Abstract Number: 659 • 2015 ACR/ARHP Annual Meeting
Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Ivette Essers^1,2, Carmen Stolwijk^1,2, Adrien Etcheto³, Anna Molto⁴, Filip van Den Bosch⁵, Désirée van der Heijde⁶, Robert B.M. Landewé^7,8, Astrid van Tubergen^1,2, Maxime Dougados^4,9 and Annelies Boonen^1,10, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹Rheumatology Department, Hôpital Cochin, Paris, France, ¹⁰Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The self-administered comorbidity questionnaire (SCQ) was developed to understand the impact of 13 common comorbidities on functioning and resource utilisation. In patients with ankylosing…
Abstract Number: 2570 • 2014 ACR/ARHP Annual Meeting
Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis
Itziar Quinzanos¹, Phat Luong¹, Sushmitha Bobba², J. Steuart Richards³, Vikas Majithia⁴, Lisa A. Davis⁵ and Liron Caplan⁶, ¹Rheumatology, Denver VA Medical Center, Denver, CO, ²Rheumatology/Research, Department of Veterans Affairs, Denver, CO, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁵Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO
Background/Purpose Patients with new onset ankylosing spondylitis (AS) and those naïve to the Ankylosing Spondylitis Disease Activity Score (ASDAS) have voiced confusion over the use…
Abstract Number: 2459 • 2013 ACR/ARHP Annual Meeting
Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis
Désirée M. van Der Heijde¹, Philip J. Mease², Aileen L. Pangan³, Sumati A Rao³, Naijun Chen³ and Mary Cifaldi³, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) was approved in the European Union for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation…
Abstract Number: 1364 • 2012 ACR/ARHP Annual Meeting
Development, Sensibility and Reliability of a New Case-Finding Questionnaire, the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease
Khalid A. Alnaqbi¹, Zahi Touma¹, Laura A. Passalent², Sindhu R. Johnson¹, George A. Tomlinson³, Adele Carty¹ and Robert D. Inman¹, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: Inflammatory bowel disease (IBD) encompasses Crohn's disease, ulcerative colitis, and indeterminate colitis. Articular involvement [(peripheral arthritis and axial spondyloarthritis (axSpA)] is the most common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].